197 related articles for article (PubMed ID: 31044475)
1. Is oxidative stress an issue in peritoneal dialysis?
Roumeliotis S; Eleftheriadis T; Liakopoulos V
Semin Dial; 2019 Sep; 32(5):463-466. PubMed ID: 31044475
[TBL] [Abstract][Full Text] [Related]
2. Oxidative Stress in Patients Undergoing Peritoneal Dialysis: A Current Review of the Literature.
Liakopoulos V; Roumeliotis S; Gorny X; Eleftheriadis T; Mertens PR
Oxid Med Cell Longev; 2017; 2017():3494867. PubMed ID: 29750088
[TBL] [Abstract][Full Text] [Related]
3. Biocompatible dialysis fluids for peritoneal dialysis.
Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
[TBL] [Abstract][Full Text] [Related]
4. Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve?
Chung SH; Stenvinkel P; Bergström J; Lindholm B
Perit Dial Int; 2000; 20 Suppl 5():S57-67. PubMed ID: 11229614
[TBL] [Abstract][Full Text] [Related]
5. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
[TBL] [Abstract][Full Text] [Related]
6. Unfavorable Effects of Peritoneal Dialysis Solutions on the Peritoneal Membrane: The Role of Oxidative Stress.
Roumeliotis S; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
Biomolecules; 2020 May; 10(5):. PubMed ID: 32423139
[TBL] [Abstract][Full Text] [Related]
7. Study of Protein Oxidative Stress, Antioxidant Vitamins and Inflammation in Patients Undergoing either Hemodialysis or Peritoneal Dialysis.
Marques de Mattos A; Afonso Jordão A; Abrão Cardeal da Costa J; Garcia Chiarello P
Int J Vitam Nutr Res; 2014; 84(5-6):261-8. PubMed ID: 26255547
[TBL] [Abstract][Full Text] [Related]
8. The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?
Perl J; Nessim SJ; Bargman JM
Kidney Int; 2011 Apr; 79(8):814-24. PubMed ID: 21248712
[TBL] [Abstract][Full Text] [Related]
9. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).
Lee HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Ahn C; Kim MJ; Shin SK
Perit Dial Int; 2005; 25(3):248-55. PubMed ID: 15981773
[TBL] [Abstract][Full Text] [Related]
10. Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis.
Wang J; Zhu N; Yuan W
Nephron; 2015; 129(3):155-63. PubMed ID: 25765060
[TBL] [Abstract][Full Text] [Related]
11. Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis.
De Los Ríos T; Pérez-Martínez J; Portoles J; Lichodziejewska-Niemierko M; Rivera M; Nowicki M; Książek A; Tato AM; Bohnhorst C; Feriani M
Perit Dial Int; 2016 9-10; 36(5):569-72. PubMed ID: 27659931
[TBL] [Abstract][Full Text] [Related]
12. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.
Kawanishi K; Honda K; Tsukada M; Oda H; Nitta K
Perit Dial Int; 2013; 33(3):242-51. PubMed ID: 23123670
[TBL] [Abstract][Full Text] [Related]
13. Evidence for Biocompatible Peritoneal Dialysis Solutions.
Nataatmadja M; Cho Y; Johnson DW
Contrib Nephrol; 2017; 189():91-101. PubMed ID: 27951555
[TBL] [Abstract][Full Text] [Related]
14. Glucose degradation products in peritoneal dialysis fluids: how they can be avoided.
Wieslander A; Linden T; Kjellstrand P
Perit Dial Int; 2001; 21 Suppl 3():S119-24. PubMed ID: 11887805
[TBL] [Abstract][Full Text] [Related]
15. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
[TBL] [Abstract][Full Text] [Related]
16. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation.
Ha H; Yu MR; Choi HN; Cha MK; Kang HS; Kim MH; Lee HB
Perit Dial Int; 2000; 20 Suppl 5():S10-8. PubMed ID: 11229606
[TBL] [Abstract][Full Text] [Related]
17. Effects of bicarbonate/lactate solution on peritoneal advanced glycosylation end-product accumulation.
Park MS; Kim JK; Holmes C; Weiss MF
Perit Dial Int; 2000; 20 Suppl 5():S33-8. PubMed ID: 11229610
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress, inflammation, and peritoneal dialysis: A molecular biology approach.
Innico G; Gobbi L; Bertoldi G; Rigato M; Basso A; Bonfante L; Calò LA
Artif Organs; 2021 Oct; 45(10):1202-1207. PubMed ID: 34037984
[TBL] [Abstract][Full Text] [Related]
19. [Biocompatibility of peritoneal dialysis fluids].
Boulanger E; Moranne O; Wautier MP; Rougier JP; Ronco P; Pagniez D; Wautier JL
Nephrol Ther; 2005 Mar; 1(1):14-22. PubMed ID: 16895663
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal dialysis solutions low in glucose degradation products--evidence for clinical benefits.
Tomo T
Perit Dial Int; 2008 Jun; 28 Suppl 3():S123-7. PubMed ID: 18552241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
